We are live on ! Find out more
MTNB icon

Matinas BioPharma
MTNB

42 hedge funds and large institutions have $6.91M invested in Matinas BioPharma in 2024 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 10 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

23% more capital invested

Capital invested by funds: $5.61M → $6.91M (+$1.3M)

0% less ownership

Funds ownership: 0.24% → 0.23% (-0%)

18% less funds holding

Funds holding: 51 → 42 (-9)

20% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 10

70% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 10

Holders
42
Holders Change
-9
Holders Change %
-17.65%
% of All Funds
0.6%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
8
Reduced
10
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$133K
2
Bank of America
Bank of America
North Carolina
+$30.8K
3
Northern Trust
Northern Trust
Illinois
+$16.2K
4
SW
Simplicity Wealth
New Jersey
+$14.3K
5
UBS Group
UBS Group
Switzerland
+$10.7K

Top Sellers

Rank Fund Capital Flow
1
CCM
Connective Capital Management
California
-$68.7K
2
SIG
Sargent Investment Group
Maryland
-$49.3K
3
VF
Virtu Financial
New York
-$35K
4
Wells Fargo
Wells Fargo
California
-$29.7K
5
Bank of New York Mellon
Bank of New York Mellon
New York
-$16.6K
Name Holding Trade Value Shares
Change 		Change in
Stake
NWMG
26
National Wealth Management Group
Ohio
$11.3K – – –
TRCT
27
Tower Research Capital (TRC)
New York
$7.91K -$2.54K -214 -27%
DAS
28
Dynamic Advisor Solutions
Arizona
$7.48K – – –
BCM
29
Bridgeway Capital Management
Texas
$7.18K -$16.6K -1,400 -73%
Bank of New York Mellon
30
Bank of New York Mellon
New York
$5.46K -$16.6K -1,400 -78%
TW
31
Trajan Wealth
Arizona
$5.07K +$4.44K +374 New
RPC
32
Rossmore Private Capital
Connecticut
$4.74K – – –
CG
33
Clarus Group
Texas
$3.25K – – –
Royal Bank of Canada
34
Royal Bank of Canada
Ontario, Canada
$3K +$772 +65 +45%
JWCA
35
J.W. Cole Advisors
Florida
$2.91K – – –
CFS
36
CRA Financial Services
New Jersey
$2.71K – – –
Osaic Holdings
37
Osaic Holdings
Arizona
$2.7K – – –
Fidelity Investments
38
Fidelity Investments
Massachusetts
$1.35K +$356 +30 +43%
SPIA
39
Steward Partners Investment Advisory
New York
$824 – – –
EWA
40
EverSource Wealth Advisors
Alabama
$557 – – –
RIL
41
Rothschild Investment LLC
Illinois
$179 – – –
IA
42
IFP Advisors
Florida
$174 – – –
CCM
43
Connective Capital Management
California
– -$68.7K -6,352 Closed
VF
44
Virtu Financial
New York
– -$35K -3,258 Closed
XT
45
XTX Topco
Cayman Islands
– -$16.5K -1,523 Closed
TSS
46
Two Sigma Securities
New York
– -$4.13K -382 Closed
BCM
47
Bayesian Capital Management
New York
– -$4.07K -376 Closed
CFG
48
Cooper Financial Group
California
– -$3.01K -278 Closed
Susquehanna International Group
49
Susquehanna International Group
Pennsylvania
– -$2.97K -275 Closed
HFM
50
Hartford Financial Management
Connecticut
– -$541 -50 Closed
1
2
3

MTNB Hedge Fund Activity: Q1 2024 in Review

42 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q1 2024, worth a combined $6.91M — up 23% from $5.61M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of MTNB and 3 opened new positions — a net loss of 7 holders — while 10 trimmed existing stakes and 8 added.

The largest buyer was Geode Capital Management, adding an estimated $133K. The largest seller was Connective Capital Management, exiting entirely with an estimated $68.7K sold.

  • 42 institutional investors held Matinas BioPharma (MTNB) as of Q1 2024, down from 51 in Q4 2023.
  • Funds reported $6.91M of Matinas BioPharma stock for Q1 2024, up 23% quarter-over-quarter.
  • 3 funds opened new Matinas BioPharma positions in Q1 2024 and 10 closed out, a net change of -7 holders.
  • The largest Matinas BioPharma buyer in Q1 2024 was Geode Capital Management, an estimated $133K added.
  • The largest Matinas BioPharma seller in Q1 2024 was Connective Capital Management, an estimated $68.7K sold.

Based on aggregated 13F filings for Q1 2024.